Enanta- It is just the beginning of good news
ENTA presented positive SVR12 data of SAPPHIRE-I –oral regimen (ENTA’s /ABT-450 boosted Abbvie’s ritonavir, ABT-267 and ABT-333) plus ribavirin where SVR12 rates were 95% in patients with HCV genotype 1a infection (n=322) and 98% in patients with HCV genotype 1b infection (n=151). This is data from the first of six Phase III HCV trial of ENTA/AbbVie's using its oral IFN free regimen. With More data to be announced in the next six months from other ongoing trials (Table 1) and regulatory filing in 2nd half of 2014 we expect ENTA shares to appreciate further. We are positive on the PhIII study outcome and approval by 2015.
